Profile data is unavailable for this security.
About the company
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
- Revenue in USD (TTM)64.99m
- Net income in USD-4.30m
- Incorporated2001
- Employees107.00
- LocationSanara Medtech Inc1200 Summit Avenue, Suite 414FORT WORTH 76102United StatesUSA
- Phone+1 (817) 529-2300
- Websitehttps://sanaramedtech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 266.86m | 49.00 | -- | 6.01 | -- | 3,294.56 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Verastem Inc | 0.00 | -87.37m | 275.85m | 73.00 | -- | 4.80 | -- | -- | -4.07 | -4.07 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -71.39 | -62.70 | -88.82 | -75.18 | -- | -- | -- | -406.17 | -- | -- | 0.3379 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Codexis Inc | 70.14m | -76.24m | 276.59m | 174.00 | -- | 3.16 | -- | 3.94 | -1.12 | -1.12 | 1.03 | 1.24 | 0.3625 | 5.43 | 2.31 | 403,120.70 | -39.41 | -17.13 | -50.48 | -20.23 | 81.74 | 77.29 | -108.69 | -37.04 | 2.53 | -- | 0.00 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Poseida Therapeutics Inc | 64.70m | -123.43m | 278.18m | 330.00 | -- | 2.65 | -- | 4.30 | -1.38 | -1.38 | 0.7175 | 1.08 | 0.2068 | -- | 7.15 | 196,069.70 | -39.45 | -40.70 | -49.32 | -47.72 | -- | -- | -190.76 | -233.49 | -- | -14.93 | 0.361 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Sanara Medtech Inc | 64.99m | -4.30m | 279.72m | 107.00 | -- | 6.18 | -- | 4.30 | -0.5219 | -0.5219 | 7.85 | 5.25 | 0.9635 | 1.90 | 8.37 | 607,381.70 | -6.58 | -17.73 | -8.17 | -22.07 | 87.92 | 88.08 | -6.83 | -17.13 | 1.04 | -18.75 | 0.1786 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Xeris Biopharma Holdings Inc | 163.91m | -62.26m | 280.20m | 377.00 | -- | -- | -- | 1.71 | -0.4525 | -0.4525 | 1.19 | -0.0491 | 0.4914 | 0.9012 | 4.68 | 434,785.20 | -18.66 | -43.60 | -24.99 | -56.57 | 82.52 | 78.23 | -37.98 | -143.08 | 1.23 | -2.01 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Vanda Pharmaceuticals Inc. | 192.64m | 2.51m | 284.01m | 203.00 | 111.29 | 0.5153 | 51.46 | 1.47 | 0.0439 | 0.0439 | 3.35 | 9.47 | 0.3004 | 11.60 | 5.69 | 948,965.50 | 0.3912 | 6.61 | 0.4547 | 7.62 | 92.32 | 90.55 | 1.30 | 15.18 | 4.92 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Monte Rosa Therapeutics Inc | 0.00 | -135.35m | 284.34m | 133.00 | -- | 1.58 | -- | -- | -2.64 | -2.64 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -41.90 | -- | -47.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| Eliem Therapeutics Inc | 0.00 | -35.12m | 284.78m | 9.00 | -- | 2.61 | -- | -- | -1.31 | -1.31 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -28.61 | -- | -29.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Chromadex Corp | 83.57m | -4.94m | 285.48m | 106.00 | -- | 9.96 | -- | 3.42 | -0.0659 | -0.0659 | 1.11 | 0.3795 | 1.53 | 2.25 | 21.38 | 788,396.30 | -9.06 | -42.11 | -14.00 | -65.14 | 60.76 | 59.68 | -5.91 | -30.64 | 1.70 | -- | 0.0008 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Akebia Therapeutics Inc | 194.62m | -51.93m | 287.15m | 167.00 | -- | -- | -- | 1.48 | -0.2778 | -0.2778 | 1.04 | -0.1572 | 0.6512 | 2.22 | 4.89 | 1,165,407.00 | -17.37 | -37.42 | -28.19 | -56.00 | 78.76 | 69.13 | -26.68 | -82.25 | 1.03 | -7.64 | 8.46 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Nektar Therapeutics | 90.12m | -276.06m | 288.29m | 137.00 | -- | 2.29 | -- | 3.20 | -1.46 | -1.46 | 0.4743 | 0.6844 | 0.1626 | 1.91 | 25.08 | 657,824.80 | -49.80 | -31.02 | -55.82 | -34.63 | 62.53 | 78.04 | -306.31 | -372.21 | 6.14 | -21.17 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| XOMA Corp | 4.76m | -46.30m | 288.32m | 13.00 | -- | 3.21 | -- | 60.60 | -4.04 | -4.04 | 0.4148 | 7.72 | -- | -- | -- | 366,000.00 | -- | -4.55 | -- | -4.94 | -- | -- | -858.15 | -31.87 | -- | -- | 0.583 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| Invivyd Inc | 0.00 | -198.64m | 288.52m | 94.00 | -- | 1.50 | -- | -- | -1.81 | -1.81 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -64.88 | -- | -73.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -116.80m | 289.88m | 131.00 | -- | 1.95 | -- | -- | -3.05 | -3.05 | 0.00 | 4.27 | 0.00 | -- | -- | 0.00 | -53.15 | -46.30 | -57.90 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Medifast Inc | 897.81m | 67.76m | 290.80m | 634.00 | 4.30 | 1.38 | 3.58 | 0.3239 | 6.20 | 6.20 | 82.15 | 19.29 | 2.88 | 3.37 | -- | 1,416,106.00 | 21.71 | 41.25 | 32.62 | 69.38 | 73.15 | 73.20 | 7.55 | 10.06 | 2.25 | -- | 0.00 | 49.18 | -32.94 | 16.43 | -30.75 | 12.25 | 5.59 | 17.72 |
Data as of May 06 2024. Currency figures normalised to Sanara Medtech Inc's reporting currency: US Dollar USD
6.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 188.36k | 2.18% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 132.84k | 1.54% |
| Geode Capital Management LLCas of 31 Dec 2023 | 74.68k | 0.87% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 53.40k | 0.62% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 30.91k | 0.36% |
| Columbia Management Investment Advisers LLCas of 31 Dec 2023 | 16.03k | 0.19% |
| Janney Montgomery Scott LLC (Investment Management)as of 31 Mar 2024 | 14.35k | 0.17% |
| Diametric Capital LPas of 31 Dec 2023 | 13.61k | 0.16% |
| Salem Investment Counselors, Inc.as of 31 Mar 2024 | 11.21k | 0.13% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2023 | 10.33k | 0.12% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
